共 36 条
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial
被引:43
作者:
Mancia, Giuseppe
[1
,2
]
Parati, Gianfranco
[1
,3
]
Revera, Miriam
[1
,3
]
Bilo, Grzegorz
[1
,3
]
Giuliano, Andrea
[3
]
Veglia, Fabrizio
[4
]
Crepaldi, Gaetano
[5
]
Zanchetti, Alberto
[6
,7
]
机构:
[1] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy
[2] Osped San Gerardo, Med Clin, I-20052 Monza, Italy
[3] IRCCS, Ist Auxol Italiano, Dept Cardiol, I-20149 Milan, Italy
[4] IRCCS, Ctr Cardiol Monzino, Biostat Unit, I-20138 Milan, Italy
[5] Univ Padua, Med Clin 1, I-35128 Padua, Italy
[6] Univ Milan, Ctr Clin Physiol & Hypertens, Milan, Italy
[7] IRCCS, Ist Auxol Italiano, I-20145 Milan, Italy
来源:
BMJ-BRITISH MEDICAL JOURNAL
|
2010年
/
340卷
关键词:
COA REDUCTASE INHIBITORS;
EUROPEAN-SOCIETY;
CARDIOVASCULAR-DISEASE;
HYPERTENSIVE PATIENTS;
MEASURING DEVICES;
ATORVASTATIN;
PRAVASTATIN;
SIMVASTATIN;
CORONARY;
THERAPY;
D O I:
10.1136/bmj.c1197
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Design Randomised placebo controlled double blind trial. Setting 13 hospitals in Italy Participants 508 patients with mild hypertension and hypercholesterolaemia, aged 45 to 70 years. Intervention Participants were randomised to antihypertensive treatment (hydrochlorothiazide 25 mg once daily or fosinopril 20 mg once daily) with or without the addition of a statin (pravastatin 40 mg once daily). Main outcome measures Clinic and ambulatory blood pressure measured every year throughout an average 2. 6 year treatment period. Results Both the group receiving antihypertensive treatment without pravastatin (n=254) (with little change in total cholesterol) and the group receiving antihypertensive treatment with pravastatin (n=253) (with marked and sustained reduction in total cholesterol and low density lipoprotein cholesterol) had a clear cut sustained reduction in clinic measured systolic and diastolic blood pressure as well as in 24 hour, and day and night, systolic and diastolic blood pressure. Pravastatin performed slightly worse than placebo, and between group differences did not exceed 1.9 (95% confidence interval -0.6 to 4.3, P=0.13) mm Hg throughout the treatment period. This was also the case when participants who remained on monotherapy with hydrochlorothiazide or fosinopril throughout the study were considered separately. Conclusions Administration of a statin in hypertensive patients in whom blood pressure is effectively reduced by concomitant antihypertensive treatment does not have an additional blood pressure lowering effect.
引用
收藏
页数:9
相关论文